Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
304 studies found for:    nash
Show Display Options
Rank Status Study
1 Withdrawn Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Condition: Non-Alcoholic Steatohepatitis
2 Not yet recruiting Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)
Conditions: Obesity;   Weight Loss;   Body Weight;   Nonalcoholic Steatohepatitis;   Nonalcoholic Fatty Liver Disease;   NAFLD
Intervention: Device: Embospheres Microspheres
3 Active, not recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
4 Terminated
Has Results
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Steatohepatitis (NASH);   Hepatic Steatosis
Interventions: Drug: Omega-3-acid ethyl esters (Lovaza);   Drug: Placebo
5 Recruiting BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Condition: Non-Alcoholic Steatohepatitis
Interventions: Device: Suspected NASH BreathID test with 13C-Octanoate;   Device: Suspected NASH Breath test with 13C Methacetin
6 Completed
Has Results
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: obeticholic acid;   Drug: placebo
7 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Condition: Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions: Drug: Elafibranor;   Drug: Placebo
8 Recruiting Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease
Conditions: Healthy;   NAFLD (Non-Alcoholic Fatty Liver Disease);   NASH (Non-Alcoholic Steatohepatitis)
Interventions: Other: NAFLD/NASH - Placebo;   Dietary Supplement: NAFLD/NASH - Vitamin E
9 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
10 Recruiting A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH
Condition: Non-alcoholic Fatty Liver Disease
Interventions: Drug: MSDC-0602K;   Drug: Placebo capsules
11 Not yet recruiting Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
Condition: Non-alcoholic Steatohepatitis (NASH)
Interventions: Drug: LMB763;   Drug: Placebo
12 Completed Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GR-MD-02;   Drug: Placebo
13 Recruiting Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH
Conditions: Obesity;   Nonalcoholic Steatohepatitis;   Nonalcoholic Fatty Liver Disease
Intervention: Behavioral: Comprehensive Lifestyle Intervention
14 Recruiting Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conditions: Non-alcoholic Steatohepatitis;   Fibrosis;   Liver Diseases
Interventions: Drug: Emricasan (5 mg);   Drug: Emricasan (50 mg);   Drug: Placebo
15 Recruiting Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
Condition: NASH
Interventions: Drug: MT-3995;   Drug: Placebo
16 Completed Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
17 Recruiting A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis
18 Recruiting Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Condition: Non Alcoholic Steatohepatitis (NASH)
Interventions: Drug: Obeticholic Acid;   Drug: Placebo
19 Completed Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Condition: Non-Alcoholic Steatohepatitis(NASH)
Interventions: Drug: Active treatment;   Drug: Placebo
20 Recruiting Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
Condition: NASH Related Decompensated Cirrhosis
Interventions: Drug: Fecal Microbiota Transplantation;   Drug: Standard Treatment;   Other: Weight Reduction

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years